Personalized Cannabinoid Formulations With Non-Combustible Dosing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cannabinoid products for medical use, particularly among cancer patients and the aging population, lack personalized dosing, fail to address specific symptoms, and pose risks due to combustion-based delivery methods and potential drug interactions.

Innovation Solution

Cannabinoid-based products tailored to individual needs, combined with a digital platform for personalized care regimens, utilizing advanced algorithms to optimize treatment protocols, and non-combustible delivery systems for precise dosing and enhanced bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If cannabinoid products use combustion-based delivery methods, then ease of operation is improved, but harmful factors increase due to health risks and cannabis use disorder

Engineering Contradiction:

Improveease of useVSAvoidhealth risks

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent changes the physical and chemical parameters of cannabinoid delivery by replacing combustion with alternative methods such as vaporization, tinctures, capsules, and edibles. This fundamentally alters the delivery mechanism to eliminate harmful combustion byproducts while maintaining effective cannabinoid delivery to the user.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent extracts and eliminates the harmful combustion process from cannabinoid delivery while retaining the therapeutic benefits. By separating the cannabinoid active ingredients from the combustion method, the invention provides delivery systems that avoid health risks associated with smoking and burning cannabis.

Inventive Principle:

Principle #2Taking out (Extraction)

2Manufacturing precision

If standardized cannabinoid products are used, then manufacturing precision is improved, but adaptability decreases due to lack of personalized dosing

Engineering Contradiction:

Improvestandardized dosingVSAvoidpersonalized treatment

Core Design Contradiction:

Manufacturing precisionVSAdaptability or versatility

Solution Approach 1:

The patent implements dynamic dosing systems that allow treatment plans to be adjusted and personalized based on individual patient needs, responses, and conditions. The system transitions from static standardized products to dynamic, adaptable formulations that can be customized for each patient while maintaining manufacturing precision through controlled formulation processes.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent segments cannabinoid products into different delivery forms, dosages, and formulations that can be selectively combined and customized for individual patients. This segmentation allows the system to maintain standardized manufacturing of individual components while enabling personalized combination and dosing strategies.

Inventive Principle:

Principle #1Segmentation

3Adaptability or versatility

If multiple cannabinoid products are used simultaneously, then versatility is improved, but harmful factors increase due to drug interactions and polypharmacy

Engineering Contradiction:

Improvetreatment optionsVSAvoiddrug interactions

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The patent implements feedback mechanisms through digital platforms that monitor patient responses, track interactions with other medications, and adjust treatment plans accordingly. This feedback loop enables the safe combination of multiple cannabinoid products by continuously assessing interactions and modifying dosages or formulations to prevent harmful effects.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent introduces digital health platforms and care coordination systems as intermediaries that manage the complexity of multiple cannabinoid products. These intermediary systems track interactions, coordinate with other medications, and provide guidance to ensure safe polypharmacy practices while maintaining treatment versatility.

Inventive Principle:

Principle #24Intermediary (Mediator)

4Device complexity

If cannabinoid products lack personalized formulations, then device complexity is reduced, but measurement precision decreases in addressing specific symptoms

Engineering Contradiction:

Improveproduct formulationVSAvoidsymptom targeting

Core Design Contradiction:

Device complexityVSMeasurement precision

Solution Approach 1:

The patent segments treatment into specific symptom-targeted cannabinoid formulations, where different products address different conditions (e.g., pain, anxiety, sleep). This segmentation allows each product to be relatively simple while the combination provides precise symptom targeting through coordinated use of specialized formulations.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250352560A1Cannabinoid-based compositions, products, and methods for supportive care

Publication Date: 2025.11.20 EO CARE INC

AI summary

Disclosed herein, inter alia, are methods of improving an outcome of a subject, the methods comprising: administering a composition comprising a cannabinoid to the subject based on a treatment plan that is based on the subject's data, the cannabinoid intended to cause an improved outcome of the subject, wherein the outcome comprises one or more of: (i) reducing a condition of the subject, (ii) improving mobility of the subject and reducing difficulty of performing general activities by the subject, (iii) reducing difficulty of performing daily living activities by the subject, or (iv) reducing difficulty of performing activities related to work, social, or leisure time by the subject.